Is Melatonin Bad for Your Liver or Kidneys? 

You've heard it a hundred times: "Be careful what you put in your body — everything goes through your liver and kidneys." It's good instinct. But when it comes to melatonin, the NIH's own drug safety database finds no evidence of clinically apparent liver injury from supplemental melatonin — and an emerging body of research suggests melatonin may actually support both organs rather than burden them. Here's what more than two decades of clinical data actually show.

Table of Contents

1. How Melatonin Is Processed in Your Body
2. What Clinical Evidence Shows About Melatonin and the Liver
3. Does Melatonin Actually Protect the Liver?
4. What Clinical Evidence Shows About Melatonin and the Kidneys
5. Who Should Be Cautious: Real Caveats, Not Fearmongering
6. Why Dosage and Formulation Affect Safety
7. BioAbsorb Liposomal Melatonin: Precise Dosing for Organ-Friendly Use
8. Frequently Asked Questions
9. Conclusion

1. How Melatonin Is Processed in Your Body

Melatonin is a small-molecule hormone — molecular weight just 232 daltons — synthesized primarily by the pineal gland from the amino acid tryptophan. Unlike many drugs, it is not a foreign compound your body must neutralize. Your liver produces and metabolizes endogenous melatonin every night, primarily via the CYP1A2 enzyme pathway, converting it into 6-sulfatoxymelatonin before urinary excretion by the kidneys. This pathway is highly efficient: a 2016 safety review in Clinical Drug Investigation found that even intravenous doses of 100 mg in healthy volunteers — orders of magnitude beyond any supplement dose — cleared without adverse effects, with a half-life of approximately 46 minutes.

The fact that melatonin is endogenous matters enormously for organ safety. Your liver and kidneys have processed melatonin your entire life; supplemental doses simply add to a physiological process already running. At typical supplement doses of 0.5–5 mg, the metabolic load on liver enzymes is minimal. StatPearls notes no established LD50 in animals even at 800 mg/kg — an extraordinarily high safety threshold. Compare that to common household substances: the LD50 of caffeine in rats is roughly 192 mg/kg. Melatonin's safety window is not comparable to most compounds people take without a second thought.

The kidneys' role is primarily elimination. Roughly 89% of a melatonin dose is excreted in urine within 24 hours as the sulfate metabolite. Unlike NSAIDs or certain antibiotics that can damage renal tubules through their metabolites, melatonin's breakdown products carry no known nephrotoxic properties. This pharmacokinetic profile — rapid metabolism, endogenous compound, clean renal elimination — explains why decades of research have produced no confirmed case of melatonin-induced kidney damage in healthy adults.

2. What Clinical Evidence Shows About Melatonin and the Liver

The most authoritative source on this question is LiverTox, the NIH's database tracking every substance implicated in drug-induced liver injury (DILI). LiverTox's entry on melatonin is unambiguous: melatonin has not been implicated in causing serum enzyme elevations or clinically apparent liver injury, even in studies that performed extensive biochemical testing. A particularly rigorous 6-month randomized controlled trial in 791 adults with primary insomnia found no treatment-related trends in any clinical laboratory tests — including liver function panels — over half a year of daily supplementation.

This finding holds across different populations. A systematic review searched PubMed, Scopus, and the Cochrane Library through late 2020 and found that across all available clinical trials, melatonin was not associated with liver harm in any study. Randomized trials in patients with diabetes, insomnia, and various metabolic conditions — groups already carrying some degree of liver stress — showed no melatonin-related hepatotoxicity. Melatonin is also not listed or discussed in major reviews of herbal and dietary supplement hepatotoxicity, despite being one of the most-used supplements in the world.

It is worth distinguishing melatonin from supplements that have caused liver problems. Black cohosh, high-dose green tea extract, kava, and certain weight-loss compounds have documented DILI case reports. Melatonin has none. After roughly 30 years as a commercial supplement in the United States, with millions of users annually, the absence of confirmed hepatotoxicity cases is meaningful evidence of safety — not an absence of data.

3. Does Melatonin Actually Protect the Liver?

The evidence goes further than "not harmful." Multiple clinical trials suggest melatonin may actively support liver health, particularly in people with fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) affects an estimated 25% of the global adult population and is driven by oxidative stress and chronic inflammation — two processes where melatonin is well-documented to intervene. A 2020 randomized double-blind clinical trial assigned 45 NAFLD patients to either 6 mg melatonin daily or placebo for 12 weeks. The melatonin group showed statistically significant improvements in alanine aminotransferase (ALT, p=0.011), aspartate aminotransferase (AST, p=0.034), inflammatory marker hs-CRP, blood pressure, body weight, and the grade of fatty liver on imaging.

A systematic review and meta-analysis of 5 randomized clinical trials in NAFLD patients confirmed melatonin significantly reduced GGT levels by 33 IU/L and ALP by 8 IU/L — both markers of liver stress — compared to placebo. A separate 100-patient RCT found melatonin significantly decreased liver enzymes over 3 months, with fatty liver grade improving in significantly more melatonin patients than controls (p=0.001). These are not marginal findings — they represent consistent directional evidence across independent trials.

The mechanism is well-established. Melatonin is a potent antioxidant and anti-inflammatory agent — it scavenges reactive oxygen species that accumulate in hepatocytes under metabolic stress, downregulates pro-inflammatory cytokines like TNF-α and IL-6, and activates protective AMPK signaling. Liver cells carry melatonin receptors (MT1 and MT2), and extrapineal melatonin synthesis has been identified in liver tissue itself, suggesting the organ actively uses melatonin for cellular maintenance. BioAbsorb's liposomal melatonin, with 80–95% bioavailability versus 15–20% for standard tablets, delivers melatonin systemically more efficiently — meaning less wasted dose and a more consistent absorption profile.

4. What Clinical Evidence Shows About Melatonin and the Kidneys

The kidney safety profile of melatonin is similarly reassuring — and, like the liver evidence, the research has evolved toward a protective picture rather than a risk one. A 2023 comprehensive review in Molecules examined melatonin's effects across kidney disease models and found consistent evidence that typical supplement doses of 2–10 mg have a favorable renal safety profile. Clinical trials in patients with diabetic kidney disease and CKD showed melatonin reduced urinary protein, improved glomerular filtration rate, and decreased both serum creatinine and blood urea nitrogen (BUN) — the two primary markers of kidney stress.

One of the most striking demonstrations came from a 2025 randomized double-blind placebo-controlled trial published in the Journal of Pineal Research. Researchers randomized 40 chronic kidney disease patients into melatonin (10 mg twice daily) or placebo before coronary angiography — a procedure carrying high AKI risk in CKD. Among patients receiving placebo, 60% developed contrast-induced acute kidney injury. In the melatonin group, only 25% developed AKI — a statistically significant 58% relative reduction (p=0.025). The melatonin group also showed significantly lower oxidative stress markers at every measured time point. This is a meaningful result in a high-risk population.

At the population scale, a meta-analysis of 31 animal studies in Frontiers in Physiology found melatonin produced significant reductions in BUN (weighted mean difference -30.00, p<0.00001) and serum creatinine (-0.91, p<0.00001) versus controls in renal ischemia-reperfusion models. Multiple mechanisms are proposed: melatonin reduces ROS-induced tubular cell damage, suppresses the renin-angiotensin system, inhibits inflammatory fibrosis pathways, and stabilizes mitochondrial function in renal cells. The pattern across both human trials and mechanistic studies consistently points in one direction — melatonin is not a kidney stressor but a kidney supporter.

5. Who Should Be Cautious: Real Caveats, Not Fearmongering

The positive safety picture does not mean melatonin is appropriate for everyone without consideration. StatPearls specifically flags dialysis patients as requiring caution, because dialysis impairs the elimination of melatonin metabolites — potentially extending the compound's duration of action and increasing next-day sedation risk. This is a pharmacokinetic concern about clearance, not toxicity. Patients on dialysis should discuss melatonin with their nephrologist before use; lower doses (0.5–1 mg) are sensible if they proceed.

Patients with advanced liver cirrhosis warrant similar thought. Cirrhosis severely impairs CYP1A2 activity — the enzyme that clears melatonin — meaning the supplement's half-life is substantially extended. One published case report documented a possible flare in a patient with primary sclerosing cholangitis after melatonin use; the mechanism is unclear but the case illustrates the principle: when the clearance pathway is compromised, even safe substances can accumulate. The clinical review of melatonin in hepatic disorders advises that in autoimmune hepatitis specifically, melatonin should be avoided until more evidence is available, due to melatonin's immune-modulatory effects potentially interacting with disease activity.

For the healthy adult majority — people using melatonin for sleep support, jet lag, or shift-work recovery — none of these caveats apply. A 2023 review of long-term melatonin administration concluded that no clinically significant adverse effects have been consistently identified, and that adverse event profiles in long-term trials are comparable to placebo. The population most likely to be reading a supplement article is exactly the population for whom the evidence base is most reassuring.

6. Why Dosage and Formulation Affect Safety

One underappreciated aspect of melatonin safety discussions is that dose size matters enormously — and most people in North America are using doses 10 to 20 times higher than what research shows is effective. A 2016 safety review in Clinical Drug Investigation found that long-term use of doses above 3 mg of controlled-release melatonin can cause next-day drowsiness in some individuals. The 5 mg, 10 mg, and 20 mg tablets widely sold in US convenience stores and pharmacies reflect regulatory history, not pharmacology. Most sleep researchers recommend starting with 0.5 mg to 1.5 mg — a dose that achieves physiological plasma levels without the receptor desensitization that may occur at pharmacological doses.

Formulation affects both efficacy and the organ burden you place on your body. Standard melatonin tablets have bioavailability of just 15–20%, meaning 80–85% of each dose requires processing before reaching circulation. Wide variability in tablet absorption — ranging from 1% to 74% across individuals due to first-pass liver metabolism — means many users unknowingly take doses far higher than intended. With a higher-bioavailability format, you need less active ingredient to achieve the same plasma concentration, which directly reduces the metabolic work for the liver.

Liposomal delivery changes this equation. By encapsulating melatonin in phospholipid vesicles, liposomal formats largely bypass first-pass liver metabolism via lymphatic absorption. A 5 mg liposomal dose delivers systemic melatonin with far greater efficiency than the same label dose in a standard tablet, with less total compound lost to first-pass metabolism for the liver to process. For people with any degree of liver sensitivity, this is a meaningful formulation advantage. BioAbsorb's graduated dropper design allows dosing in 0.25 mg increments, making it practical to use the minimum effective dose rather than defaulting to a fixed high dose.

7. BioAbsorb Liposomal Melatonin: Precise Dosing for Organ-Friendly Use

If the research says anything actionable about melatonin and organ health, it is this: use the lowest effective dose, in a form that delivers it efficiently. BioAbsorb Liposomal Liquid Melatonin is designed around both principles. Each full dropper delivers 5 mg of melatonin via liposomal encapsulation — achieving 80–95% bioavailability compared to 15–20% for standard tablets, and onset in 15–30 minutes versus 60–90 minutes for conventional forms.

That bioavailability gap has a direct safety implication. Because liposomal absorption is so much more complete, a lower effective label dose can achieve the same systemic melatonin exposure as a much larger standard tablet — meaning less total compound processed by the liver, less inter-individual variability in how much actually reaches your bloodstream, and more consistent dosing from night to night. The graduated dropper — allowing increments as small as 0.25 mg — is not just a convenience feature. It lets you titrate to the minimum dose that works for you, rather than accepting the fixed-dose engineering of a standard 5 mg tablet. Manufactured in a GMP-certified, Health Canada-approved Canadian facility, every batch is third-party tested with a certificate of analysis available on request.

The formulation is non-GMO, vegan, gluten-free, and free of artificial flavours and colours — with a natural mixed berry flavour. For the person asking whether melatonin is safe for their liver and kidneys, the answer the evidence supports is: yes, at physiological doses in a healthy adult. And using a precisely dosed, highly bioavailable format means you can take the smallest dose that achieves your sleep goal — which is always the right approach when thinking about long-term supplementation.

Frequently Asked Questions

Can melatonin cause liver damage?

Based on current clinical evidence, no. The NIH LiverTox database — which tracks every substance associated with drug-induced liver injury — has never implicated melatonin in causing elevated liver enzymes or liver damage, even after decades of widespread use. Several randomized trials in populations with existing liver disease (including NAFLD and cirrhosis) have found no liver harm from melatonin supplementation. The exception: patients with advanced cirrhosis or autoimmune hepatitis should consult their physician, as impaired enzyme clearance can affect how long melatonin stays in the system.

Can melatonin cause kidney damage?

There are no confirmed clinical cases of melatonin causing kidney damage in healthy adults. A 2023 review of melatonin in kidney diseases found that typical supplement doses of 2–10 mg have a favorable renal safety profile and that multiple clinical trials have observed melatonin actually improving kidney function markers. Dialysis patients are advised to use caution due to impaired melatonin clearance, which can prolong its effects — this is a pharmacokinetic consideration, not evidence of kidney damage.

Does melatonin go through the liver?

Yes. Melatonin is primarily metabolized in the liver via the CYP1A2 enzyme pathway, then excreted by the kidneys as 6-sulfatoxymelatonin. This is a normal, efficient physiological process — your body performs it every night with the melatonin your pineal gland produces naturally. Liposomal melatonin formulations partially bypass first-pass liver metabolism via lymphatic absorption, which reduces the metabolic load and produces more consistent blood levels. This is one practical reason liposomal delivery is preferred for individuals thinking about long-term supplementation.

Is melatonin safe to take every night long term?

A 2023 review of chronic melatonin administration concluded that no clinically significant adverse effects have been consistently identified with long-term use, and that adverse event rates in long-term trials are generally comparable to placebo. The strongest caution for long-term use is to use the lowest effective dose and avoid controlled-release formulations above 3 mg, which may cause next-day drowsiness.

Who should not take melatonin?

People on dialysis should consult their nephrologist before using melatonin, as impaired clearance may extend the duration of effect. People with autoimmune hepatitis or advanced cirrhosis should also consult their doctor, as impaired CYP1A2 activity can slow melatonin metabolism. Pregnant and breastfeeding women are advised to avoid melatonin due to insufficient safety data in those populations, per StatPearls clinical guidance. For healthy adults, the evidence base for safety is strong.

Does melatonin interact with medications metabolized by the liver?

Melatonin is metabolized by CYP1A2, which also processes caffeine, theophylline, and some antidepressants. Drugs that inhibit CYP1A2 — notably fluvoxamine — can raise melatonin plasma concentrations significantly (up to 17-fold in some reports). CYP1A2 inducers like tobacco smoke can reduce melatonin levels. This isn't a reason to avoid melatonin, but it's worth discussing with a prescribing physician if you take medications that interact with this enzyme pathway.

Conclusion

The research record on melatonin and organ safety is more reassuring than most people realize — and in some respects, actively encouraging. No confirmed cases of melatonin-induced liver or kidney injury exist in the clinical literature, the NIH's own drug safety database finds no hepatotoxic signal after decades of widespread use, and emerging clinical trials suggest melatonin may reduce oxidative organ stress rather than create it. If you're supplementing for sleep or circadian support, using the lowest effective dose in a highly bioavailable format — like BioAbsorb's liposomal melatonin, which achieves 80–95% bioavailability with precise dropper dosing — is the practical way to align with both the efficacy and safety evidence. As with any supplement, if you have a known liver or kidney condition, check with your physician first.

Research References

1. Melatonin — LiverTox. NIH, NCBI Bookshelf (2020). NIH drug injury database confirming melatonin has never been implicated in liver enzyme elevations or hepatotoxicity, including across a 6-month RCT in 791 insomnia patients.
2. The Safety of Melatonin in Humans. Clinical Drug Investigation, Vol. 36 (2016). Safety review finding only mild, placebo-comparable adverse effects from short- and long-term use; no organ toxicity even at extreme doses.
3. Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders. Iranian Journal of Pharmaceutical Research, Vol. 20 (2021). Clinical review finding beneficial effects on NAFLD and drug-induced hepatitis; no evidence of liver harm across all available trials.
4. Melatonin in Non-Alcoholic Fatty Liver Disease: A Randomized Double Blind Clinical Trial. Phytotherapy Research, Vol. 35 (2020). 45-patient RCT: 6 mg/day melatonin for 12 weeks significantly improved ALT, AST, fatty liver grade, and hs-CRP vs. placebo.
5. The Effects of Melatonin in Patients with NAFLD: A Randomized Controlled Trial. Journal of Research in Medical Sciences, Vol. 22 (2017). 100-patient RCT: melatonin significantly decreased liver enzymes and improved fatty liver grade (p=0.001) vs. placebo.
6. Melatonin Supplementation on Liver Indices in NAFLD: Systematic Review and Meta-Analysis. Phytotherapy Research, Vol. 35 (2020). Meta-analysis of 5 RCTs: melatonin significantly improved GGT (−33 IU/L) and ALP (−8 IU/L) vs. placebo.
7. Melatonin — StatPearls. NIH, NCBI Bookshelf (2024). Confirms no established LD50 at 800 mg/kg; only minor adverse effects at supraphysiological doses; caution advised for dialysis patients.
8. Melatonin Treatment in Kidney Diseases. Molecules, Vol. 28 (2023). Review demonstrating favorable renal safety at 2–10 mg and clinical evidence of improved kidney function markers across CKD populations.
9. Melatonin for Renal Ischemia-Reperfusion Injury: Systematic Review and Meta-Analysis. Frontiers in Physiology, Vol. 12 (2021). 31-study meta-analysis: melatonin significantly reduced BUN (WMD −30.00, p<0.00001) and serum creatinine vs. controls.
10. Melatonin on Kidney Function Against Contrast Media-Induced Damage in CKD. Journal of Pineal Research, Vol. 77 (2025). RCT: melatonin reduced contrast-induced AKI from 60% to 25% (p=0.025) in 40 CKD patients.
11. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurology International, Vol. 15 (2023). Review: no clinically significant adverse effects consistently identified with long-term use; adverse event rates comparable to placebo.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.